Tag: SLO10

JC: Lopinavir/Ritonavir in the treatment of COVID-19

We have been following the RECOVERY trial closely over the last few months. It’s the largest RCT of therapeutics for COVID-19 in the world and it’s already shown that hydroxychloroquine and azithromycin don’t work in

azithromycin stemlyns covid-19

JC: Azithromycin in patients hospitalised with COVID-19

As we near the end of 2020, it is worth taking a moment to reflect on what a year it has been. At the beginning of the year we were first hearing about a respiratory

JC: Convalescent plasma in COVID 19 patients.

This month the BMJ has published a trial on the use of convalescent plasma in the treatment of admitted patients with COVID-19 (the PLACID trial). Convalescent plasma therapy basically takes plasma, together with antibodies from

JC: Spot the Difference, what can we do about petechiae? St Emlyn’s

Back in 2013, I wrote a post here on petechiae in well kids; it received a phenomenal number of views for reasons I don’t quite understand (I think it ended up as a link somewhere

JC: Early plasma use in traumatic brain injury. St Emlyn’s

There seems to be a lot of really interesting papers on Traumatic Brain Injury (TBI) this year. A welcome relief from COVID 19 perhaps but also a reminder that other pathologies exist and that TBI

JC: Finger on the Pulse?

If you’re an avid follower of FOAM, you’ll have seen many assertions that manual pulse checks by healthcare providers during cardiac arrest are pretty unreliable at best. The most commonly advocated alternatives are EtCO2 increase

JC: Should we rubber STAAMP prehospital TXA?

This post is co-published with our friends at REBEL EM. Background: It almost seems that when it comes to the use of the antifibrinolytic agent tranexamic acid (TXA) in trauma, one argument has just been

JC: Blood Products in Trauma – What’s the Best (I)TACTIC?

Bleeding trauma patients present a couple of challenges to us in the Emergency Department. Increasingly, our aging population continues to engage in energetic daily pursuits while increasing numbers are prescribed newer direct oral anticoagulant treatments

JC: Hydroxychloroquine in the the treatment of hospitalised COVID19 patients.

We previously covered the RECOVERY trial press release on the use of HCQ for hospitalised patients with COVID19. This is a UK based platform trial (more on this later) looking at patients admitted to hospital

JC: Antibiotics or Surgery for appendicitis.

Appendicitis is a common problem in the emergency department, and for many years the standard of care has been to perform surgery to resolve it. When I trained in surgery (before transferring to EM) this